Compare SONO & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SONO | ATAI |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2018 | 2025 |
| Metric | SONO | ATAI |
|---|---|---|
| Price | $16.25 | $4.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $19.67 | $15.88 |
| AVG Volume (30 Days) | 1.3M | ★ 4.4M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $1,443,276,000.00 | $4,089,000.00 |
| Revenue This Year | $5.04 | N/A |
| Revenue Next Year | $6.53 | N/A |
| P/E Ratio | $30.23 | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $9.97 | $2.00 |
| 52 Week High | $19.82 | $6.73 |
| Indicator | SONO | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 61.07 | 56.47 |
| Support Level | $15.83 | $3.44 |
| Resistance Level | $17.81 | $4.68 |
| Average True Range (ATR) | 0.59 | 0.27 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 76.21 | 55.09 |
Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.